China's First PMTA Non-Clinical Lab by Feelm Analysis Center

Jul.29.2022
China's First PMTA Non-Clinical Lab by Feelm Analysis Center
China's first non-clinical PMTA testing laboratory has been built by the Analytical Testing and Safety Assessment Center (ATSA).

Recently, it has been reported that the Analytical Testing and Safety Assessment Center (referred to as the "Safety Assessment Center") of Smoler has established China's first PMTA (pre-market tobacco application) comprehensive non-clinical testing laboratory. The laboratory currently covers PMTA non-clinical research requirements, including material safety, harmful and potentially harmful constituents (HPHCs) and toxicity testing.


This is the first PMTA testing laboratory established domestically, which will assist the global leading provider of closed-system electronic cigarette solutions, Smoore, and its flagship brand FEELM, in further improving product safety and helping partner brands successfully pass PMTA certification.


The only laboratory in China that covers all substances in HPHCs.


Before this, electronic cigarette companies that wanted to enter the international market had to rely on third-party partners to complete PMTA testing, which was expensive and time-consuming. With the establishment of a new domestic laboratory, FEELM's brand partners can more easily undergo PMTA certification, increasing their chances of entering the international market.


Dr. Long, the director of the Smyrna Evaluation Center, has revealed that the FDA has placed significant emphasis on HPHCs and has identified a list of 33 substances to be tested. The Smyrna Evaluation Center is currently capable of testing 37 substances and is the only laboratory in the country that has the ability to test all substances included in the list of HPHCs.


The laboratory conducted tests using the world-leading HPHCs (harmful and potentially harmful constituents) database developed by Philip Morris International, which is based on multiple authoritative international toxicity databases. In addition, the lab incorporated advanced computational toxicology software to predict unidentified and potential harmful constituents not included in the database, further enhancing Philip Morris's safety assessment capabilities.


Assist brand clients in entering the overseas market.


Since the establishment of its first basic research institute in 2017, Simoer has been continuously expanding its global leading detection projects and building a comprehensive product safety verification system. Currently, Simoer's safety evaluation center has established the industry's first E&L (extractables and leachables) analysis testing laboratory, raising the material safety standard for electronic atomization to medical grade, and recently completed a toxicity testing laboratory that is now open to FEELM customers.


Smol intends to become the driving force behind electronic cigarette brands approaching the FDA and other regulatory agencies, allowing the brand to enter a broader overseas market. To date, eight of their products have been approved by the FDA for market release, with several produced by Smol, indicating FDA recognition of the processes and testing mechanisms in their new laboratory in China. Concurrently, Smol is collaborating with brand partners and FEELM customers to expand their testing scope and provide stronger support for product design, while also preparing to release safety reports.


This article contains excerpts or reprints from third-party sources, and their copyright belongs to the original media and authors. If there is any infringement, please contact us for deletion. Any organization or individual who wants to reprint must contact the author and should not directly reprint.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Smoore International Issues 2025 Interim Profit Warning: First-Half Earnings Expected to Drop 21%–35% YoY
Smoore International Issues 2025 Interim Profit Warning: First-Half Earnings Expected to Drop 21%–35% YoY
Smoore International has issued a profit warning, expecting net profit for the six months ended June 30, 2025, to decline by approximately 21% to 35% year-on-year, projected to range between 443 million and 541 million yuan.
Jul.16 by 2FIRSTS.ai
Malta Health Authority Issues Warning on Nicotine Pouches, Plans Inclusion in Future Tobacco Control Strategy
Malta Health Authority Issues Warning on Nicotine Pouches, Plans Inclusion in Future Tobacco Control Strategy
Malta’s health authorities warn of the dangers of nicotine pouches as several European countries initiate bans.
Jul.08
UK E-Cigarette Approved List Update: 320 New SKUs Approved, Including ELFBAR, SKE, MASKKING, and More (July 28 - August 1)
UK E-Cigarette Approved List Update: 320 New SKUs Approved, Including ELFBAR, SKE, MASKKING, and More (July 28 - August 1)
Between July 28 and August 1, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) e-cigarette product notification database listed 320 new SKUs, including e-cigarettes, multi-flavor pods, and accessories from brands like ELFBAR, IVG, SKE, MASKKING, and INNOKIN.
Aug.05 by 2FIRSTS.ai
FDA Launches National Priority Review Program: Drugs Aligned with U.S. Priorities May Be Approved in as Little as One Month
FDA Launches National Priority Review Program: Drugs Aligned with U.S. Priorities May Be Approved in as Little as One Month
The FDA has launched the Commissioner’s National Priority Voucher (CNPV) program, reducing the review time for certain drugs to as little as 1–2 months. While the program currently applies only to pharmaceuticals, it demonstrates the FDA’s capacity to reform its review pathways. Whether a similar mechanism could extend to tobacco products now appears to be a matter of timing and technical details.
Jun.18
Ireland Finds "Nicotine-Free" E-Cigarettes Contain Nicotine; Involves McKesse, JNR, and Crystal Brands
Ireland Finds "Nicotine-Free" E-Cigarettes Contain Nicotine; Involves McKesse, JNR, and Crystal Brands
Ireland’s HSE found some “nicotine-free” e-cigarettes contain nicotine, misleading consumers and risking addiction. The products were seized, and a warning issued. Experts warn nicotine addiction is underestimated, and health impacts remain unclear.
Aug.01 by 2FIRSTS.ai
E-cigarette Explosion During Charging Causes Fire, Destroying Three Houses in the UK; Authorities Issue Urgent Warning
E-cigarette Explosion During Charging Causes Fire, Destroying Three Houses in the UK; Authorities Issue Urgent Warning
A recent e-cigarette explosion during charging in Gainsborough, UK, caused a fire that made three houses uninhabitable. The fire department confirmed it was due to overheating, and trading standards officials warn against buying cheap e-cigarettes.
Jul.02 by 2FIRSTS.ai